Proteomics International Laboratories Secures Australian Patent Acceptance for PromarkerEndo

Proteomics International Laboratories (ASX: PIQ) has received a notice of acceptance from IP Australia for its PromarkerEndo patent application, strengthening protection around the company’s blood test for diagnosing endometriosis.

The accepted claims cover methods that use specific protein biomarkers measured in blood samples to diagnose endometriosis and guide treatment selection, with protection expected to extend until March 2041 subject to grant and maintenance requirements.

PromarkerEndo has demonstrated high diagnostic accuracy in published clinical studies, including for early-stage disease, supporting Proteomics’ efforts to develop a non-invasive alternative for women presenting with symptoms.

The Australian milestone adds to granted patent protection already secured in the US and Japan, as Proteomics progresses commercialisation and potential partnership and licensing opportunities.

Patent Extends Commercial Pathway

Australia is a key market in Proteomics’ commercialisation plans, where the company is positioning PromarkerEndo as a tool that could improve diagnostic timing while reducing reliance on invasive procedures.

The accepted patent strengthens the intellectual property position around the test and supports future discussions with potential commercial partners and licensees in the local healthcare market.

“The acceptance of this patent is another major achievement and further validation of the novelty and commercial potential of PromarkerEndo,” chief executive officer and managing director David Morris said.

“Securing patent protection in our home jurisdiction is another critical step in our global commercialisation strategy.”

Diagnosis Delay Targeted

Endometriosis—which affects one in nine women and girls— occurs when tissue similar to the lining of the uterus grows elsewhere in the body.

Diagnosis of the condition currently takes an average of seven years, creating a significant need for earlier and more accessible testing pathways than the current one that can involve surgical laparoscopy.

PromarkerEndo is designed as a blood test that could help rule in or rule out the need for invasive surgery among women presenting with symptoms of endometriosis.

The technology is based on Proteomics’ Promarker biomarker discovery platform, which searches for protein fingerprints in samples to distinguish between people who have a disease and those who do not.

Proteomics expects more timely and accurate diagnosis could improve patient outcomes and reduce healthcare costs compared with existing diagnostic pathways.

Global Protection Strategy

Proteomics is pursuing additional PromarkerEndo patent protection across Canada, China, Europe, India, Singapore, and South Korea as it builds coverage around the diagnostic technology.

Granted protection is already in place in Japan and the US, with the Australian application now progressing following IP Australia’s notice of acceptance.

The expanding patent portfolio is intended to support commercialisation across multiple healthcare markets while providing a platform for future partnerships and licensing arrangements.

Proteomics is continuing to position PromarkerEndo around the unmet need for faster endometriosis diagnosis, with its clinical performance and growing patent coverage forming the basis of that commercial pathway.